Le Lézard
Classified in: Health
Subjects: PDT, PLW

Green Mountain Biotech and Kamedis Announce First Patent in China for Unique Herb-Based Acne and Skin Relief Solution


Clinically-tested solution, based on a proprietary blend of six herbs used in Traditional Chinese Medicine, helps relieve symptoms of acne and other skin inflammation conditions.

TEL AVIV, Israel, Sept. 29, 2022 /PRNewswire/ -- Green Mountain Biotech (GMB), the developer of the synergistic herbal skincare combination Botaniplextm, and Kamedis, its parent company and the developer and marketer of end products featuring Botaniplextm, announced today the acceptance of their first shared patent in China.

The patent, No. ZL 201780074679.0, is for a proprietary six-herb composition named Botaniplextm CLEAR for use in treating or preventing acne. Kamedis products containing Botaniplextm CLEAR have been found to be effective in clinical studies to relieve the symptoms of acne, as well as other painful skin lesions, such as boils and folliculitis.

Botaniplextm CLEAR's antimicrobial, prebiotic, anti-inflammatory and antioxidant properties provide inflammation control, restore microbiome balance, and assist the body in healing from problematic skin conditions. The AC Spot Treatment, the final product featuring the patented Botaniplextm CLEAR formula, will be marketed globally by Kamedis.

"I'm very proud to have led the team that developed Botaniplextm CLEAR, and I'm excited to bring effective, safe skin solutions to people suffering from acne and other painful skin issues," said Dr. Yonit Bomstein, Co-Founder and Head of R&D at GMB. "Botaniplextm CLEAR has the potential to improve the day-to-day lives of millions of  consumers, and we're thrilled to provide access to our formula to those who can benefit from it."

"The granting of our first Chinese patent is a meaningful moment for both GMB and Kamedis. We are honored that our unique herbal combination has been validated by Chinese regulators, and that we can now introduce our solution to the Chinese market," said Roni Kramer, Founder and CEO of Kamedis.

Kamedis and Green Mountain Biotech are currently seeking a distributor for their products in China.

About Green Mountain Biotech:  GMB develops, manufactures and markets best-in-class, premium quality dermocosmetic ingredients extracted from Chinese medicinal botanicals for the cosmetic and personal care industries. Backed by leading scientists and researchers, the botanical materials undergo rigorous and thorough testing for efficacy and safety, from field to final botanical blends.

About Kamedis: Kamedis develops, and markets dermatologist-tested, clinically proven, botanical skincare products targeted to relieve symptoms of chronic skin conditions. Kamedis products are sold worldwide via trusted distribution partners and E-commerce platforms.

Contact:
Roni Kramer CEO&Founder
[email protected]


These press releases may also interest you

at 06:30
Qomolangma Acquisition Corp. (the "Company") announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-K for the period ended December 31, 2023,...

at 06:30
Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from the biopharma industry and leading cancer centers, including those within the Caris...

at 06:13
MolecuLight Inc., the pioneer in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, proudly announces the presentation of findings from multiple MolecuLight studies in nine clinical posters at the...

at 06:05
FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently available medicines using its Helicontm peptide platform, and ARTBIO, Inc. ("ARTBIO"), a clinical-stage...

at 06:05
Rockwell Medical, Inc. (the "Company") , a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the...

at 06:05
Aurinia Pharmaceuticals Inc. (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney...



News published on and distributed by: